A prospective, randomized, phase II study to assess the schemas of retreatment with Lutathera® in patients with new progression of an intestinal, well-differentiated neuroendocrine tumor (ReLUTH)

BACKGROUND: Although neuroendocrine tumors (NET) are classed as rare, they have a high prevalence and their incidence is increasing. Effective treatment with lutetium (17)-[177Lu]Lu-oxodotreotide (Lutathera®) is possible in patients with well-differentiated NET, improving progression-free survival (...

Descripción completa

Detalles Bibliográficos
Autores principales: Deshayes, Emmanuel, Assenat, Eric, Meignant, Laetitia, Bardiès, Manuel, Santoro, Lore, Gourgou, Sophie
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Study Protocol
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9773621/
https://www.ncbi.nlm.nih.gov/pubmed/36550428
http://dx.doi.org/10.1186/s12885-022-10443-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9773621/
https://www.ncbi.nlm.nih.gov/pubmed/36550428
http://dx.doi.org/10.1186/s12885-022-10443-4

Ejemplares similares